Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.59 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.59 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 5/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.56 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4220632 | 0.87 | NR4A1 (0.72) | NR4A2NR4A1NR4A3ALOX5MAOB | |
| SCHEMBL7901142 | 0.83 | NR4A2 (0.74) | MEN1KMT2ANR4A2MAOBSRD5A2 | |
| SCHEMBL6208174 | 0.82 | L3MBTL1 (0.70) | NR4A2NR4A1NR4A3ALOX5MAOB | |
| SCHEMBL1419819 | 0.82 | L3MBTL1 (0.70) | NR4A2NR4A1NR4A3ALOX5MAOB | |
| SCHEMBL13427458 | 0.81 | MEN1 (0.71) | MEN1KMT2ANR4A2NR4A1NR4A3 | |
| SCHEMBL10770964 | 0.81 | MEN1 (0.71) | MEN1KMT2ANR4A2NR4A1NR4A3 | |
| SCHEMBL2451027 | 0.81 | MEN1 (0.71) | MEN1KMT2ANR4A2NR4A1NR4A3 | |
| SCHEMBL1066614 | 0.80 | FFAR1 (0.70) | NR4A2NR4A1NR4A3ALOX5MAOB | |
| SCHEMBL1426961 | 0.80 | MEN1 (1.00) | MEN1KMT2ANR4A2NR4A1NR4A3 | |
| SCHEMBL3272467 | 0.79 | NR4A1 (0.60) | NR4A2NR4A1NR4A3ALOX5MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2202215-B1 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| EP-2049459-B1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEM F (FR) | 2013-10-02 | — | — | EP | disclosed |
| US-8101804-B2 | Process for the synthesis of (E)-stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2012-01-24 | — | — | US | disclosed |
| EP-2202215-A2 | Novel process for the synthesis of (E)-Stilbene derivatives which makes it possible to obtain resveratrol and piceatannol | Clariant Specialty Fine Chemicals (France) (FR) | 2010-06-30 | — | — | EP | disclosed |
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2010-01-07 | — | — | US | disclosed |
| EP-2049459-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | Clariant Specialty Fine Chemicals (France) (FR) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008012321-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF (E)-STILBENE DERIVATIVES WHICH MAKES IT POSSIBLE TO OBTAIN RESVERATROL AND PICEATANNOL | CLARIANT SPECIALTY FINE CHEMICALS (FRANCE) (FR) | 2008-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004483-A1 | Novel Process For The Synthesis Of (E)-Stilbene Derivatives Which Makes It Possible To Obtain Resveratrol And Piceatannol | SQLE, SUCLA2, SORD | MEN1 2235/4885KMT2A 2929/4885NR4A2 899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.